Loading clinical trials...
Loading clinical trials...
A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants
Conditions
Interventions
rozanolixizumab
Placebo
Locations
1
United Kingdom
Up0106 001
London, United Kingdom
Start Date
April 22, 2021
Primary Completion Date
April 11, 2022
Completion Date
April 11, 2022
Last Updated
March 7, 2024
NCT06679413
NCT05845645
NCT04867642
NCT05292131
NCT04444466
NCT04136444
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions